<DOC>
	<DOCNO>NCT02188693</DOCNO>
	<brief_summary>The primary purpose study evaluate whether gemcitabine single agent superior observation improve progression-free survival ( PFS ) patient metastatic breast cancer ( MBC ) achieve disease control initial six cycle PG first-line treatment</brief_summary>
	<brief_title>Gemcitabine Single Agent Maintenance Chemotherapy Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically Confirmed Metastatic , Recurrent Breast Cancer Age 18 Years ECOG Performance Status 02 Premenopausal Postmenopausal Breast Cancer Patients With Measurable NonMeasurable Lesions , Who Are Candidates Chemotherapy Life Expectancy ≥ 3 Months Patients May Have Received Prior Neoadjuvant Adjuvant Taxane Regimen Long Has Been 12 Months Since Completion Regimen . Patients Either May May Not Have Prior Anthracycline Containing Regimen . Prior Hormonal Therapy Treatment Metastatic Disease Allowed . But Antitumoral Hormonal Therapy Must Terminated Prior Enrollment ( Date Randomization ) Prior Radiation Therapy Allowed Long &lt; 25 % Bone Marrow Has Been Treated , Patients Must Have Recovered From Acute Toxic Effects Treatment Prior Study Enrollment.Prior Radiation Whole Pelvis Not Allowed . Prior Radiotherapy Must Completed 4 Weeks Before Study Entry . Adequate Bone Marrow Function ( ≥ ANC 1,500/ul , ≥ Platelet 100,000/ul , ≥ Hemoglobin 9.0 g/dl ) Adequate Renal Function ( ≤ Serum Creatinine 1.5 mg/dl CCr ≥ 50 ml/Min ) Adequate Liver Function ( ≤ Serum Bilirubin 1.5 mg/dl , ≤ AST/ALT x 3 Upper Normal Limit ) No Prior History Chemotherapy Metastatic , Recurrent Breast Cancer Written Informed consent Serious Uncontrolled Intercurrent Infections Serious Intercurrent Medical Psychiatric Illness , Including Active Cardiac Disease Pregnancy Breast Feeding Second Primary Malignancy ( Except Cancer Cervix Skin Other Malignancy Treated Least 5 Years Previously With Evidence Recurrence ) Documented Parenchymal Leptomeningeal Brain Metastasis Peripheral Neuropathy ≥ Grade 2 Prior Treatment With Gemcitabine Will Not Allowed . HER2 Overexpressing Breast Cancer Concomitant Trastuzumab Treatment Not Allowed</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>